Global Penny Stocks To Watch In March 2025
Global markets have recently faced challenges, with U.S. stocks experiencing significant declines amid trade policy uncertainty and inflation concerns. Despite these headwinds, investors continue to explore opportunities in various sectors, including the often-overlooked realm of penny stocks. While the term 'penny stock' may seem outdated, it still represents a valuable investment area where smaller or newer companies can offer growth potential when supported by strong financials and fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
NEXG Berhad (KLSE:DSONIC)
MYR0.27
MYR751.18M
★★★★★★
Warpaint London (AIM:W7L)
£3.65
£294.87M
★★★★★★
DXN Holdings Bhd (KLSE:DXN)
MYR0.505
MYR2.51B
★★★★★★
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)
SGD2.39
SGD9.44B
★★★★★☆
EZZ Life Science Holdings (ASX:EZZ)
A$1.69
A$81.61M
★★★★★★
Sarawak Plantation Berhad (KLSE:SWKPLNT)
MYR2.28
MYR636.19M
★★★★★★
Angler Gaming (NGM:ANGL)
SEK3.79
SEK284.19M
★★★★★★
Next 15 Group (AIM:NFG)
£2.92
£290.41M
★★★★☆☆
Cloudpoint Technology Berhad (KLSE:CLOUDPT)
MYR0.77
MYR409.33M
★★★★★★
Lever Style (SEHK:1346)
HK$1.28
HK$844.27M
★★★★★★
Click here to see the full list of 5,709 stocks from our Global Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Liuzhou Chemical Industry Co., Ltd. is a company engaged in the production and sale of hydrogen peroxide in China, with a market capitalization of approximately CN¥2.51 billion.
Operations: The company's revenue segment is primarily derived from the Chemical Industry, generating CN¥178.44 million.
Market Cap: CN¥2.51B
Liuzhou Chemical Industry's market capitalization stands at approximately CN¥2.51 billion, with a revenue segment primarily from the chemical industry generating CN¥178.44 million. The company has no debt, and its short-term assets of CN¥484.1 million significantly exceed its liabilities, indicating strong liquidity. Despite a volatile share price recently, earnings growth has been robust at 381.3% over the past year, surpassing both its historical average and industry benchmarks. Its Price-To-Earnings ratio of 26.9x suggests it may be undervalued compared to the broader Chinese market average of 38.5x, although Return on Equity remains relatively low at 16.9%.
Click here to discover the nuances of Liuzhou Chemical Industry with our detailed analytical financial health report.
Gain insights into Liuzhou Chemical Industry's past trends and performance with our report on the company's historical track record.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Wenfeng Great World Chain Development Corporation operates a commercial retail chain in China, with a market cap of CN¥5.58 billion.
Operations: The company's revenue primarily comes from its operations in China, totaling CN¥1.93 billion.
Market Cap: CN¥5.58B
Wenfeng Great World Chain Development's market cap is CN¥5.58 billion, with revenue of CN¥1.93 billion from its Chinese retail operations. The company faces challenges with a low Return on Equity of 2.6% and declining earnings, down 25.6% annually over five years. Short-term liabilities exceed short-term assets (CN¥1.8B vs CN¥1.3B), raising liquidity concerns despite having more cash than debt and sufficient interest coverage by profits. A dividend yield of 2.39% is not well supported by earnings or free cash flow, while the management team and board are relatively inexperienced with average tenures under three years each.
Navigate through the intricacies of Wenfeng Great World Chain Development with our comprehensive balance sheet health report here.
Assess Wenfeng Great World Chain Development's previous results with our detailed historical performance reports.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Harbin Gloria Pharmaceuticals Co., Ltd focuses on the research, development, production, and sale of pharmaceutical products mainly in China with a market cap of CN¥5.52 billion.
Operations: Harbin Gloria Pharmaceuticals Co., Ltd has not reported any specific revenue segments.
Market Cap: CN¥5.52B
Harbin Gloria Pharmaceuticals, with a market cap of CN¥5.52 billion, has recently become profitable, yet its Return on Equity remains low at 4.7%. The company's short-term liabilities slightly exceed its short-term assets (CN¥871.9M vs CN¥870.4M), indicating tight liquidity management despite having more cash than total debt and reducing its debt-to-equity ratio significantly over five years. Recent board changes reflect investor activism with new director appointments aiming to strengthen governance. Although earnings have grown significantly over the past five years, the presence of large one-off gains impacts financial clarity and stability assessments for potential investors in this volatile space.
Click to explore a detailed breakdown of our findings in HARBIN GLORIA PHARMACEUTICALS' financial health report.
Gain insights into HARBIN GLORIA PHARMACEUTICALS' outlook and expected performance with our report on the company's earnings estimates.
Investigate our full lineup of 5,709 Global Penny Stocks right here.
Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Jump on the AI train with fast growing tech companies forging a new era of innovation.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHSE:600423 SHSE:601010 and SZSE:002437.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
If EPS Growth Is Important To You, Hextar Global Berhad (KLSE:HEXTAR) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. In contrast to all that, many investors prefer to focus on companies like Hextar Global Berhad (KLSE:HEXTAR), which has not only revenues, but also profits. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. That means EPS growth is considered a real positive by most successful long-term investors. Hextar Global Berhad managed to grow EPS by 11% per year, over three years. That's a good rate of growth, if it can be sustained. It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. EBIT margins for Hextar Global Berhad remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 21% to RM925m. That's encouraging news for the company! In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart. Check out our latest analysis for Hextar Global Berhad While profitability drives the upside, prudent investors always check the balance sheet, too. It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. Shareholders will be pleased by the fact that insiders own Hextar Global Berhad shares worth a considerable sum. Holding RM283m worth of stock in the company is no laughing matter and insiders will be committed in delivering the best outcomes for shareholders. That holding amounts to 8.2% of the stock on issue, thus making insiders influential owners of the business and aligned with the interests of shareholders. One important encouraging feature of Hextar Global Berhad is that it is growing profits. If that's not enough on its own, there is also the rather notable levels of insider ownership. These two factors are a huge highlight for the company which should be a strong contender your watchlists. It is worth noting though that we have found 1 warning sign for Hextar Global Berhad that you need to take into consideration. Although Hextar Global Berhad certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Malaysian companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
IOI Corporation Berhad's (KLSE:IOICORP) Intrinsic Value Is Potentially 17% Below Its Share Price
IOI Corporation Berhad's estimated fair value is RM2.99 based on 2 Stage Free Cash Flow to Equity IOI Corporation Berhad's RM3.61 share price signals that it might be 21% overvalued The RM4.07 analyst price target for IOICORP is 36% more than our estimate of fair value Today we will run through one way of estimating the intrinsic value of IOI Corporation Berhad (KLSE:IOICORP) by taking the expected future cash flows and discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward. Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (MYR, Millions) RM917.4m RM999.1m RM1.00b RM1.01b RM1.03b RM1.06b RM1.09b RM1.12b RM1.16b RM1.20b Growth Rate Estimate Source Analyst x2 Analyst x4 Analyst x4 Est @ 1.22% Est @ 1.95% Est @ 2.45% Est @ 2.81% Est @ 3.06% Est @ 3.23% Est @ 3.36% Present Value (MYR, Millions) Discounted @ 8.4% RM846 RM851 RM786 RM734 RM691 RM653 RM619 RM589 RM561 RM535 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = RM6.9b After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 3.6%. We discount the terminal cash flows to today's value at a cost of equity of 8.4%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = RM1.2b× (1 + 3.6%) ÷ (8.4%– 3.6%) = RM26b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= RM26b÷ ( 1 + 8.4%)10= RM12b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is RM19b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of RM3.6, the company appears slightly overvalued at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at IOI Corporation Berhad as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.4%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Check out our latest analysis for IOI Corporation Berhad Strength Earnings growth over the past year exceeded the industry. Debt is not viewed as a risk. Weakness Dividend is low compared to the top 25% of dividend payers in the Food market. Expensive based on P/E ratio and estimated fair value. Opportunity IOICORP's financial characteristics indicate limited near-term opportunities for shareholders. Threat Dividends are not covered by cash flow. Annual earnings are forecast to decline for the next 3 years. Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a premium to intrinsic value? For IOI Corporation Berhad, we've put together three relevant factors you should assess: Risks: Every company has them, and we've spotted 2 warning signs for IOI Corporation Berhad (of which 1 is potentially serious!) you should know about. Future Earnings: How does IOICORP's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. Simply Wall St updates its DCF calculation for every Malaysian stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
TIME dotCom Berhad's (KLSE:TIMECOM) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?
TIME dotCom Berhad's (KLSE:TIMECOM) stock is up by 9.4% over the past three months. However, its weak financial performance indicators makes us a bit doubtful if that trend could continue. Specifically, we decided to study TIME dotCom Berhad's ROE in this article. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In simpler terms, it measures the profitability of a company in relation to shareholder's equity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for TIME dotCom Berhad is: 12% = RM386m ÷ RM3.3b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each MYR1 of shareholders' capital it has, the company made MYR0.12 in profit. See our latest analysis for TIME dotCom Berhad So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. On the face of it, TIME dotCom Berhad's ROE is not much to talk about. Next, when compared to the average industry ROE of 20%, the company's ROE leaves us feeling even less enthusiastic. As a result, TIME dotCom Berhad's flat net income growth over the past five years doesn't come as a surprise given its lower ROE. We then compared TIME dotCom Berhad's net income growth with the industry and found that the company's growth figure is lower than the average industry growth rate of 11% in the same 5-year period, which is a bit concerning. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if TIME dotCom Berhad is trading on a high P/E or a low P/E, relative to its industry. The high three-year median payout ratio of 55% (meaning, the company retains only 45% of profits) for TIME dotCom Berhad suggests that the company's earnings growth was miniscule as a result of paying out a majority of its earnings. In addition, TIME dotCom Berhad has been paying dividends over a period of at least ten years suggesting that keeping up dividend payments is way more important to the management even if it comes at the cost of business growth. Upon studying the latest analysts' consensus data, we found that the company's future payout ratio is expected to rise to 96% over the next three years. Still, forecasts suggest that TIME dotCom Berhad's future ROE will rise to 14% even though the the company's payout ratio is expected to rise. We presume that there could some other characteristics of the business that could be driving the anticipated growth in the company's ROE. Overall, we would be extremely cautious before making any decision on TIME dotCom Berhad. Because the company is not reinvesting much into the business, and given the low ROE, it's not surprising to see the lack or absence of growth in its earnings. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
